AstraZeneca India bags DCGI marketing nod for QTERN-once-daily anti-diabetes drug
QTERN® is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM).QTERN® combines two anti-hyperglycaemic agents with complementary mechanisms of action in a once-daily tablet. The drug comprises sodium-glucose cotransporter 2 (SGLT2) inhibitor- dapagliflozin and a dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin.
SGLT-2 inhibitors help patients achieve improved glycaemic control by reducing the reabsorption of glucose from the blood and enabling its removal via the urine. SGLT-2 inhibitors, including Forxiga (dapagliflozin), have demonstrated reductions in HbA1c and have also been shown to reduce weight and blood pressure. DPP-4 inhibitors reduce blood glucose as measured by HbA1c.
Type 2 diabetes in India is a disease of epidemic scale affecting over 63 million people. Rapid urbanization, industrialization and demographic transition resulting in altered lifestyles have been identified as the main causes for this alarming number. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen. QTERN® will provide yet another option to physicians to help them in managing type 2 diabetes of their patients.
Gagandeep Singh Bedi, Managing Director, AstraZenecaIndia said, "Type-2 diabetes is a complex disease that is at epidemic proportions, affecting more than 63 million people in India. The approval of QTERN® is good news for patients who may benefit from improved glycaemic control by adding a DPP-4 inhibitor to a SGLT-2 inhibitor in a convenient once-daily tablet"
Type 2 diabetes mellitus is a chronic disease characterised by pathophysiologic defects leading to elevated glucose levels. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen. It is estimated that more than half of people living with Type 2 diabetes mellitus are not achieving recommended HbA1c goals based on guidelines established by professional societies and advocacy organisations for diabetes management.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here